Organon & Co
(MEX:OGN)
MXN
371
0 (0%)
Market Cap: 96.69 Bil
Enterprise Value: 246.71 Bil
PE Ratio: 4.99
PB Ratio: 108.51
GF Score: 62/100 - Q1 2024 Organon & Co Earnings Call TranscriptMay 02, 2024MXN299Earnings
- Q4 2023 Organon & Co Earnings Call TranscriptFeb 15, 2024MXN270Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2023
- Q3 2023 Organon & Co Earnings Call TranscriptNov 02, 2023MXN281Earnings
- Q2 2023 Organon & Co Earnings Call TranscriptAug 08, 2023MXN360Earnings
- Q1 2023 Organon & Co Earnings Call TranscriptMay 04, 2023MXN425Earnings
- Q4 2022 Organon & Co Earnings Call TranscriptFeb 16, 2023MXN500 (-6.72%)Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Q3 2022 Organon & Co Earnings Call TranscriptNov 03, 2022MXN500Earnings
- Q2 2022 Organon & Co Earnings Call TranscriptAug 04, 2022MXN647.72Earnings
- Q1 2022 Organon & Co Earnings Call TranscriptMay 05, 2022MXN663Earnings
- Organon & Co at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Organon & Co Earnings Call TranscriptFeb 17, 2022MXN694.06Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2022
- Organon & Co at Evercore ISI HealthCONx Virtual Conference TranscriptDec 01, 2021
- Q3 2021 Organon & Co Earnings Call TranscriptNov 11, 2021MXN670 (-11.48%)Earnings
- Organon & Co at Morgan Stanley Global Healthcare Conference (Fireside Chat) TranscriptSep 13, 2021
- Q2 2021 Organon & Co Earnings Call TranscriptAug 12, 2021MXN668 (+11.52%)Earnings
Organon & Co at Piper Sandler Healthcare Conference Transcript
Nov 29, 2023 / 04:00PM GMT
Release Date Price:
MXN190
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Good morning, everyone, and let's get started. Welcome again to the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Organon. We have Kevin Ali, CEO; and Matt Walsh, CFO. Thanks gentlemen, for joining us. And certainly, lots to talk about, so I'm going to dive right in with questions here.
Kevin Ali
Organon & Co. - CEO & Director
Go ahead.
Questions & Answers
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst
So I'll start at a high level and ask how you're thinking about balancing debt paydown and capital deployment to bolster the pipeline and/or commercial portfolio. So maybe I'll start with you, Kevin.
Kevin Ali;David A. Amsellem
Organon & Co. - CEO & Director;Piper
You jumping right in the deep end first?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)